Cheryl Meguid
Overview
Explore the profile of Cheryl Meguid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cooper D, Karten J, Hoffe S, King D, Weiss M, DePeralta D, et al.
Learn Health Syst
. 2025 Jan;
9(1):e10422.
PMID: 39822915
Introduction: Learning health networks (LHNs) improve clinical outcomes by applying core tenets of continuous quality improvements (QI) to reach community-defined outcomes, data-sharing, and empowered interdisciplinary teams including patients and caregivers....
2.
Yee E, Torphy R, Myers E, Meguid C, Franklin O, Sugawara T, et al.
Ann Surg Oncol
. 2024 Aug;
31(12):8340-8351.
PMID: 39120842
Background: Assessment of individual tumor biology and response to systemic therapy in pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge. The significance of anthropometric (body composition) changes during chemotherapy as...
3.
McCranie A, Lee A, Leonard L, Vemuru S, Huynh V, DAngelo J, et al.
J Surg Res
. 2024 May;
PMID: 38811259
Introduction: It is common for cancer patients to seek a second opinion for a variety of reasons. Understanding what drives patients to choose to receive treatment with their second opinion...
4.
Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, et al.
EClinicalMedicine
. 2023 Jun;
60:102018.
PMID: 37304495
Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases...
5.
Ziogas I, Franco S, Schmoke N, Meguid C, Murphy C, Al-Musawi M, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831527
Background: Current evidence on overall survival (OS) between invasive pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) is limited to single-center reports. We aimed to compare the characteristics,...
6.
Oba A, Wu Y, Colborn K, Karam S, Meguid C, Al-Musawi M, et al.
Br J Surg
. 2022 Feb;
109(5):450-454.
PMID: 35136963
Background: Neoadjuvant treatment is important for improving the rate of R0 surgical resection and overall survival outcome in treating patients with pancreatic ductal adenocarcinoma (PDAC). However, the true efficacy of...
7.
Wu Y, Oba A, Lin R, Watanabe S, Meguid C, Schulick R, et al.
J Gastrointest Oncol
. 2021 Nov;
12(5):2475-2483.
PMID: 34790408
Pancreatic cancer (PC) is likely to become the second leading cause of malignancy-associated mortality within the next 10 years and surgery remains the best hope for cure. The introduction of...
8.
Wu Y, Oba A, Beaty L, Colborn K, Franco S, Harnke B, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33922344
Intraductal papillary mucinous neoplasms (IPMN) are common but difficult to manage since accurate tools for diagnosing malignancy are unavailable. This study tests the diagnostic value of the main pancreatic duct...
9.
Mueller A, Piper M, Goodspeed A, Bhuvane S, Williams J, Bhatia S, et al.
Cancer Res
. 2021 Feb;
81(12):3255-3269.
PMID: 33526513
Stromal fibrosis activates prosurvival and proepithelial-to-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma (PDAC). In patient tumors treated with neoadjuvant stereotactic body radiation therapy (SBRT), we found upregulation of fibrosis,...
10.
Zakem S, Mueller A, Meguid C, Torphy R, Holt D, Schefter T, et al.
HPB (Oxford)
. 2020 Dec;
23(7):1072-1083.
PMID: 33277184
Background: The role of neoadjuvant stereotactic body radiation therapy (SBRT) in patients with borderline resectable pancreas cancer (BRPC) and locally advanced pancreas cancer (LAPC) remains controversial. Methods: We retrospectively evaluated...